AI Article Synopsis
- Adjuvants like QS-21 are essential for boosting vaccine effectiveness, but QS-21 faces challenges such as limited availability, complex synthesis, and toxicity.
- Researchers are working on creating simpler and safer analogues of QS-21 that maintain strong immunogenic properties.
- The analogues VA05 and VA06 show promising results, generating similar antibody responses as QS-21 while being less toxic, making them potential candidates for better vaccine adjuvants.
Article Abstract
Adjuvants are crucial agents that enhance the immunogenicity of vaccines, with QS-21 being particularly noteworthy for its potent immunostimulatory properties. QS-21, a saponin-based vaccine adjuvant isolated from the bark of , has garnered significant attention. However, its application as vaccine adjuvant is limited due to its scarcity, complex chemical synthesis, and inherent toxicity. This study aims to develop QS-21 analogues with simplified structures, enhanced immunogenicity, and reduced toxicity. Our research findings indicate that the antibody titers generated by the analogues VA05 and VA06 in conjunction with the antigen are comparable to those induced by QS-21. With their lower toxicity, VA05 and VA06 emerge as promising candidates for next-generation adjuvant development, potentially surpassing QS-21 in both efficacy and safety.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.jmedchem.4c02173 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Experimental medicine study with stabilised native-like HIV-1 Env immunogens drives long-term antibody responses, but lacks neutralising breadth.
EBioMedicine
January 2025
Imperial College London, Department of Infectious Disease, UK. Electronic address:
Background: We report findings from an experimental medicine study of rationally designed prefusion stabilised native-like HIV envelope glycoprotein (Env) immunogens, representative of global circulating strains, delivered by sequential intramuscular injection.
Methods: Healthy adult volunteers were enrolled into one of five groups (A to E) each receiving a different schedule of one of two consensus Env immunogens (ConM SOSIP, ConS UFO, either unmodified or stabilised by chemical cross-linking, followed by a boost with two mosaic Env immunogens (Mos3.1 and Mos3.
Peptide-based vaccine design against Hendra virus through immunoinformatics approach.
Vet Immunol Immunopathol
December 2024
Department of Biochemistry, Bahauddin Zakariya University, Multan 66000, Pakistan. Electronic address:
The Hendra virus (HeV) has resulted in epidemics of respiratory and neurological illnesses in animals. Humans have contracted diseases with high fatality rates as a result of infected domestic animals, but effective vaccinations and therapies are currently not available against HeV. Herein, we analyzed the proteome of HeV and constructed an effective and innovative multi-epitope vaccine using immunoinformatics techniques.
View Article and Find Full Text PDFGlutathione-Responsive Metal-Organic-Framework-Derived MnO/(A/R)TiO Nanoparticles for Enhanced Synergistic Sonodynamic/Chemodynamic/Immunotherapy.
ACS Nano
January 2025
State Key Laboratory of Inorganic Synthesis and Preparative Chemistry, College of Chemistry, Jilin University, 2699 Qianjin Street, Changchun 130012, China.
Despite the potential of sonodynamic therapy (SDT) in treating malignant tumors, the lack of effective sonosensitizers has limited its clinical implementation. In this study, we explored the relationship between the heteroatom doping concentration in metal-organic frameworks and interface formation after pyrolysis by regulating the addition of manganese sources and successfully derived Z-scheme heterojunctions MnO/(A/R)TiO (MTO) in situ from MIL-125-NH (Ti/Mn). The electron transfer pathway introduced by interfacial contact promoted carrier separation and greatly preserved the effective redox components, significantly influencing the performance of reactive oxygen species generation.
View Article and Find Full Text PDFMolecular dynamics simulation based prediction of T-cell epitopes for the production of effector molecules for liver cancer immunotherapy.
PLoS One
January 2025
School of Information and Technology, Wenzhou Business College, Wenzhou, Zhejiang, China.
Liver cancer is the sixth most frequent malignancy and the fourth major cause of deaths worldwide. The current treatments are only effective in early stages of cancer. To overcome the therapeutic challenges and exploration of immunotherapeutic options, broad spectral therapeutic vaccines could have significant impact.
View Article and Find Full Text PDFPD-L1 expression in high-risk non-muscle invasive bladder cancer is not a biomarker of response to BCG.
World J Urol
January 2025
Department of Urology, Erasmus University Medical Center, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, Room Be-304, 3015 GD, Rotterdam, The Netherlands.
Purpose: Up to 50% of high-risk non-muscle invasive bladder cancer (HR-NMIBC) patients fail Bacillus Calmette-Guérin (BCG) treatment, resulting in a high risk of progression and poor clinical outcomes. Biomarkers that predict outcomes after BCG are lacking. The antitumor effects of BCG are driven by a cytotoxic T cell response, which may be controlled by immune checkpoint proteins like Programmed Death Ligand 1 (PD-L1).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!